These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 2618982)

  • 1. Mineral balance (iron, aluminum, copper, zinc) after high-dose intravenous Desferal in a child with hemoglobin Hammersmith and Turner's syndrome.
    Hyman CB; Gonick HC; Neufeld N; Agness CL
    Am J Pediatr Hematol Oncol; 1989; 11(4):450-5. PubMed ID: 2618982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
    Ambruso DR; Mahony BS; Githens JH; Rhoades ED
    Am J Pediatr Hematol Oncol; 1982; 4(2):115-23. PubMed ID: 7114394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA; Taqi A; Deghaidi A
    Pediatr Hematol Oncol; 2004; 21(5):453-60. PubMed ID: 15205089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Desferal treatment of aluminum poisoning; effect on serum concentrations of aluminum (Al), iron (Fe) and copper (Cu)].
    Günther K; Winnefeld K; Stein G; Sperschneider H; Schröter H; Fünfstück R
    Z Urol Nephrol; 1986 Oct; 79(10):569-76. PubMed ID: 3811645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major].
    Flückiger A; Imbach P; Pfenninger E; Stocker F; Töndury P; Wagner HP; Weber J; Zuppinger K
    Helv Paediatr Acta; 1985 Sep; 40(4):293-304. PubMed ID: 4077563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of subcutaneous desferrioxamine on iron balance in young thalassemia major patients.
    De Virgiliis S; Cossu P; Toccafondi C; Sanna G; Frau F; Lobrano R; Cornacchia G; Nucaro A; Loi A; Bertolino F; Cao A
    Am J Pediatr Hematol Oncol; 1983; 5(1):73-7. PubMed ID: 6859457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron excretion in thalassemia children treated with deferoxamin methansulfonat: intravenous drip compared to the subcutaneous routes.
    Hathirat P; Areekul S; Isarangkura P; Chantachum Y
    J Med Assoc Thai; 1989 Jan; 72 Suppl 1():121-4. PubMed ID: 2732632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ; Göbel U; Christaras A; Janssen G
    Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioactive iron (59Fe) excretion through the urine and feces after intravenous iron-59 administration in congenital hemolytic anemias.
    Gyftaki H; Kesse-Elias M; Constantoulakis M; Malamos B
    J Nucl Med; 1967 May; 8(5):385. PubMed ID: 6032706
    [No Abstract]   [Full Text] [Related]  

  • 11. Urinary zinc excretion and zinc status of patients with beta-thalassemia major.
    Aydinok Y; Coker C; Kavakli K; Polat A; Nisli G; Cetiner N; Kantar M; Cetingül N
    Biol Trace Elem Res; 1999 Nov; 70(2):165-72. PubMed ID: 10535525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship.
    Silliman CC; Peterson VM; Mellman DL; Dixon DJ; Hambidge KM; Lane PA
    J Lab Clin Med; 1993 Jul; 122(1):48-54. PubMed ID: 8320490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term intravenous deferoxamine treatment for noncompliant transfusion-dependent beta-thalassemia patients.
    Tamary H; Goshen J; Carmi D; Yaniv I; Kaplinsky C; Cohen IJ; Zaizov R
    Isr J Med Sci; 1994 Aug; 30(8):658-64. PubMed ID: 8045754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral ascorbic acid and iron excretion in thalassemic children treated with desferrioxamine-methansulfonate (Desferal).
    Hathirat P; Isarangkura P; Areekul S; Pleehachinda R; Tuntawiroon M
    Birth Defects Orig Artic Ser; 1988; 23(5B):129-33. PubMed ID: 3390535
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
    Kalinowski M; Popławski A; Kaliszewski Z; Juzwiuk J
    Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of deferoxamine methanesulfonate on Trichophyton mentagrophytes.
    Kerbs S; Hutton R; Lancaster M
    Sabouraudia; 1979 Sep; 17(3):241-50. PubMed ID: 43597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chelating therapy in beta-thalassemia].
    Musumeci S; Romeo MA; Di Gregorio F; Schiliró G; Russo G
    Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rubber band technique for slow subcutaneous infusion of desferrioxamine (Desferal).
    Hathirat P; Isarangkura P; Panthangkura W; Chuansumrit A; Sasanakul W; Kanasit R
    Birth Defects Orig Artic Ser; 1988; 23(5B):123-7. PubMed ID: 3390534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload.
    Borgna-Pignatti C; Franchini M; Gandini G; Vassanelli A; De Gironcoli M; Aprili G
    Haematologica; 1998 Sep; 83(9):788-90. PubMed ID: 9825575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum ferritin concentrations in transfusion dependent beta-thalassaemia.
    George E; Wong HB; George R; Ariffin WA
    Singapore Med J; 1994 Feb; 35(1):62-4. PubMed ID: 8009283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.